

# Ziprasidone (hydrochloride)

Catalog No: tcsc1887



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

122883-93-6

**Formula:**

$C_{21}H_{22}Cl_2N_4OS$

**Pathway:**

GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein

**Target:**

Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

CP-88059 hydrochloride

**Observed Molecular Weight:**

449.4

## Product Description


Ziprasidone Hcl(CP-88059 Hcl) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Target: 5-HT receptor; Dopamine receptor

Ziprasidone (hydrochloride) is the salt form of ziprasidone, which possesses an in vitro 5-HT<sub>2A</sub>/dopamine D<sub>2</sub> receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT<sub>2A</sub> receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D<sub>2</sub> receptor antagonism. Ziprasidone also has high affinity for the 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub> and 5-HT<sub>2C</sub> receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT<sub>2</sub> and D<sub>2</sub> receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].

Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; Schizophrenia

FDA Approved Date: February 2001



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!